- Home
- CDIO vs KUST Comparison
CDIO vs KUST Comparison
Compare CDIO & KUST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDIO | KUST |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Radio And Television Broadcasting And Communications Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 4.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CDIO | KUST |
|---|---|---|
| Price | $1.51 | $1.71 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.2M | ★ 7.0M |
| Earning Date | 03-19-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $15,782.00 | ★ $19,097,965.00 |
| Revenue This Year | $1,434.82 | N/A |
| Revenue Next Year | $4,661.91 | $7.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $1.80 |
| 52 Week High | $20.55 | $1,799.40 |
Technical Indicators
Market Signals| Indicator | CDIO | KUST |
|---|---|---|
| Relative Strength Index (RSI) | 27.62 | 41.20 |
| Support Level | $1.65 | $1.80 |
| Resistance Level | $1.87 | $2.53 |
| Average True Range (ATR) | 0.17 | 0.45 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 3.54 | 0.36 |
Price Performance
Historical ComparisonAbout CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.